FDA Delays Approval for Moderna's RSV Vaccine, New Timeline Revealed
Friday, 10 May 2024, 11:00
FDA Delays Approval for Moderna's RSV Vaccine
Moderna has revealed that the FDA has pushed back the approval of their RSV vaccine to the end of May, causing speculation in the market.
No Safety or Quality Issues Detected
The biotech company confirmed that there have been no indications of safety, efficacy, or quality issues that would prevent the vaccine's approval.
Impact on Vaccine Rollout
The delay raises concerns about the timeline for the vaccine's availability and may lead to changes in market expectations.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.